Synaptogenix Inc (SNPX)

[InTheTrenches]

AF really needs to read yesterday's press release in the context of the detailed phase 2 Bryostatin results at clinicaltrials.gov (post-hoc data on 20ug Bryostatin non-memantine patients).

The 20ug non-memantine data is clear and convincing; with proper enrollment numbers, this should lead to a statistically successful trial.

From the first patient enrollment PR yesterday:

- "...patients in the bryostatin 20ug dose group not receiving concurrent memantine treatment exhibited a SIB score improvement from baseline of over 6 points. There was no corresponding treatment effect for memantine-treated patients."

- Alkon: "The potentially important persistence of the bryostatin-induced improvement in the SIB scores in our recently completed Phase 2 trial, even one month after completion of all dosing, is an effect that we hope to repeat in this confirmatory trial."

- Alkon: "Our hope is that this might translate into long lasting cognitive function benefit in advanced AD patients, and earlier stage patients..."

- Ryan: "...very positive feedback from key opinion leaders..."

-------------------

IMO, AF is mistaken in his analysis of Bryostatin.